Urelumab  (Synonyms: 乌瑞芦单抗)

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL)^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

CD137^[1]

Urelumab (0.3-1 mg/kg, 腹腔注射, 每 3 天一次, 共 6 次) 可减少人源化 4-1BB 小鼠的肿瘤体积和肿瘤重量^[2]。
Urelumab (3-30 mg/kg, 腹腔注射, 每 3 天一次, 共 6 次) 在人源化 4-1BB 小鼠中表现出高度安全性^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

934823-49-1

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized 4-1BB/TNFRSF9 Protein, Human can bind Urelumab. The EC₅₀ for this effect is 12.68 ng/mL.

• [1]. John Timmerman, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 May;95(5):510-520.  [Content Brief]

  [2]. Cheng LS, et al. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med. 2022 Sep 8;20(1):415.  [Content Brief]